Search Within

Katherine Marie Bell-McGuinn

Formats
  1. Meeting Abstract (32)
  2. Journal Article (27)
  3. Book Section (1)
Groups
  1. Gynecology Disease Management Team (35)
  2. Department of Medicine (34)
  3. Solid Tumor Oncology Division (34)
  4. GDMT, Medicine (32)
  5. Gynecologic Medicine Service (32)
  6. Surgery (9)

More Groups

People
  1. Carol Aghajanian (29)
  2. Jason Konner (13)
  3. Paul Sabbatini (11)
  4. William Tew (10)
  5. Martee Hensley (9)
  6. David Spriggs (8)

More People

Years
  1. 2021 (1)
  2. 2020 (5)
  3. 2019 (2)
  4. 2018 (4)
  5. 2017 (4)
  6. 2016 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Gynecologic Oncology (15)
  3. Clinical Cancer Research (7)
  4. Cancer Research (5)
  5. Annals of Oncology (4)
  6. Diagnostic Pathology of Ovarian Tumors (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. Elsevier B.V. (15)
  3. American Association for Cancer Research (12)
  4. Oxford University Press (4)
  5. Elsevier Science, Inc. (2)
  6. Springer (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
    Meeting Abstract

    Matulonis, U. A.; Wulf, G.; Barry, W.; Birrer, M.; Westin, S.; Spagnoletti, T.; Bell-McGuinn, K.; Obermayer, E.; Whalen, C.; Aghajanian, C.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis
    Meeting Abstract

    Kristeleit, R.; Swisher, E.; Oza, A.; Coleman, R. L.; Scott, C.; Konecny, G.; Tinker, A.; O'Malley, D. M.; Brenton, J.; Bell-Mcguinn, K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase 1 data by the gynecologic oncology group
    Meeting Abstract

    Monk, B. J.; Brady, W. E.; Lankes, H. A.; Facciabene, A.; Manjarrez, K. L.; Hershberg, R. M.; Fracasso, P. M.; Bell-Mcguinn, K. M.; Walker, J. L.; McCourt, C. K.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: An NRG/GOG study
    Meeting Abstract

    Thaker, P. H.; Brady, W. E.; Lankes, H. A.; Cohn, D. E.; Aghajanian, C.; Mutch, D. G.; Mannel, R. S.; Bell-Mcguinn, K. M.; DiSilvestro, P.; Jelovac, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer
    Meeting Abstract

    O'Cearbhaill, R. E.; Hyman, D. M.; Tew, W. P.; Iasonos, A.; Cangemi, N. A.; Aghajanian, C.; Bell-Mcguinn, K. M.; Makker, V.; Hensley, M. L.; Konner, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis
    Meeting Abstract

    McNeish, I. A.; Oza, A. M.; Coleman, R. L.; Scott, C. L.; Konecny, G. E.; Tinker, A.; O'Malley, D. M.; Brenton, J.; Kristeleit, R. S.; Bell-Mcguinn, K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
    Meeting Abstract

    Bell-Mcguinn, K. M.; Brady, W. E.; Schilder, R. J.; Fracasso, P. M.; Moore, K. N.; Walker, J. L.; Duska, L. R.; Mathews, C. A.; Chen, A.; Shepherd, S. P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
    Journal Article

    Coleman, R. L.; Sill, M. W.; Bell-Mcguinn, K.; Aghajanian, C.; Gray, H. J.; Tewari, K. S.; Rubin, S. C.; Rutherford, T. J.; Chan, J. K.; Chen, A.; more...
    Gynecologic Oncology (2015)

    Fulltext@MSK | Save
  • First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer
    Journal Article

    Shapiro, G. I.; Bell-Mcguinn, K. M.; Molina, J. R.; Bendell, J.; Spicer, J.; Kwak, E. L.; Pandya, S. S.; Millham, R.; Borzillo, G.; Pierce, K. J.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save